Revolutionary Parkinson's Gene Therapy in Development
News Nov 28, 2017
The joint project will see the company develop novel gene promoters that specifically control the expression of therapeutic genes in different sub-populations of neurones. In the first instance, UCL will use these new gene switches to develop a gene therapy-based approach for the treatment of Young-Onset Parkinson’s disease.
Commenting on the collaboration, Dr Michael Roberts, Founder and Chief Scientific Officer of Synpromics stated: “Tightly controlling the therapeutic gene is an essential element in the development of any successful gene therapy and Synpromics’ technology offers the best means to achieve that control. This collaboration will allow the company to develop a gene therapy approach for a largely unmet clinical need, where tight gene control is an absolute requirement. It also gives us the opportunity to work with UCL, one of the few world-leading institutions actively developing novel gene-based therapies.”
The collaboration is expected to last over 24 months with work being split equally between the two partners.
“We are delighted to be working with the leaders in gene control, Synpromics Ltd, to develop gene therapy for Young-Onset Parkinson’s disease. Parkinson’s is the second most common untreatable progressive brain disease and novel therapeutic approaches are required. This collaboration allows us to develop tailor-made gene therapy vectors for untreatable brain disorders,” said Dr Simon Waddington (UCL Institute for Women's Health).
Synpromics continues to drive forward with the development of its innovative approach to better control of gene function with this strategic move into CNS applications. This adds to the work already done in liver and muscle and the company’s proprietary inducible promoter platform. Synpromics works with leading clinicians focused on trying to develop cures for genetic diseases with significant unmet need, enabled by its innovative gene control technology, to improve human health.
This article has been republished from materials provided by Synpromics. Note: material may have been edited for length and content. For further information, please contact the cited source.
Two Proteins Dictate Visual System Axon StabilizationNews
Scientists have made an important discovery concerning the development of layer-specific axonal connections in the developing visual system of Drosophila flies.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE
Comments | 1 ADD COMMENT
Beverly Ogunleye | Nov 30, 2017
Am a male aged 60 and diagnosed with Parkinson"s at 59. I had some symptoms for a few years before diagnosis; stiff achy right arm and ankle, right hand tremor when typing, tiredness, body shivers, falls due to tripping. I was always active, bicycle riding to/from work daily and putting in 2 to 3,000 miles on my bicycle per year. i was on Mysoline 250mg in 3 doses for the essential tremor. Madopar 200mgfour times a day. Sifrol 1mg three times a day, I started on Health Herbal Clinic Parkinsons Disease Herbal formula treatment in November 2016, i read alot of positive reviews on their success rate treating Parkinsons disease through their PD Herbal formula and i immediately started on the treatment. Just 8 weeks into the Herbal formula treatment I had great improvements, my hand tremors seized. I am unbelievably back on my feet again, visit Health Herbal Clinic official website www. healthherbalclinic. net or email info@ healthherbalclinic. net.My have reduced my symptoms have so much reduced that now I hardly notice them.